Company intelligence / Profile preview

Isotek Systems

Oak Ridge, Tennessee, United States

Ownership: Private
Development stage: Other

Overview

Isotek Systems has, in partnership with DOE and TerraPower, extracted more than 15g of thorium-229 (expected total 40g), making medical isotopes (specifically actinium-225) available at a scale 100x greater than previous world supply, enabling large-scale clinical trial and commercialization of targeted alpha therapies for cancer.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalRadiotherapy-enabling isotope
Industry: Chemicals & Materials

Partnerships

U.S. Department of EnergyTerraPower/TerraPower IsotopesCardinal Health

Beyond the preview

Go deeper on Isotek Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isotek Systems.

Explore the full profile